Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma
J Furuse, H Ishii, K Nakachi, E Suzuki… - Cancer …, 2008 - Wiley Online Library
Sorafenib is an orally active multikinase inhibitor that targets serine and threonine, and
tyrosine kinases that are involved in tumor‐cell signal transduction and tumor angiogenesis …
tyrosine kinases that are involved in tumor‐cell signal transduction and tumor angiogenesis …
[引用][C] Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma
J FURUSE, H ISHII, K NAKACHI, E SUZUKI… - Cancer …, 2008 - pascal-francis.inist.fr
Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma CNRS Inist
Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search Advanced …
Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search Advanced …
[引用][C] Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma
J Furuse, H Ishii, K Nakachi, E Suzuki, S Shimizu… - Cancer Science, 2007 - cir.nii.ac.jp
Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.
J Furuse, H Ishii, K Nakachi, E Suzuki, S Shimizu… - Cancer …, 2007 - europepmc.org
Sorafenib is an orally active multikinase inhibitor that targets serine and threonine, and
tyrosine kinases that are involved in tumor-cell signal transduction and tumor angiogenesis …
tyrosine kinases that are involved in tumor-cell signal transduction and tumor angiogenesis …
[PDF][PDF] Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma
J Furuse, H Ishii, K Nakachi, E Suzuki, S Shimizu… - Cancer Sci, 2007 - academia.edu
Materials and Methods Patient eligibility. The eligibility criteria for enrolment in the study
were:(1) histologically confirmed HCC;(2) unresectable and incurable with ablation therapy …
were:(1) histologically confirmed HCC;(2) unresectable and incurable with ablation therapy …
Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma
J Furuse, H Ishii, K Nakachi, E Suzuki… - Cancer …, 2008 - pubmed.ncbi.nlm.nih.gov
Sorafenib is an orally active multikinase inhibitor that targets serine and threonine, and
tyrosine kinases that are involved in tumor-cell signal transduction and tumor angiogenesis …
tyrosine kinases that are involved in tumor-cell signal transduction and tumor angiogenesis …
[引用][C] Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma
J FURUSE - Cancer Sci, 2007 - cir.nii.ac.jp